Literature DB >> 18842729

Accelerated prion replication in, but prolonged survival times of, prion-infected CXCR3-/- mice.

Constanze Riemer1, Julia Schultz, Michael Burwinkel, Anja Schwarz, Simon W F Mok, Sandra Gültner, Theresa Bamme, Stephen Norley, Frank van Landeghem, Bao Lu, Craig Gerard, Michael Baier.   

Abstract

Prion diseases have a significant inflammatory component. Glia activation, which is associated with increased production of cytokines and chemokines, may play an important role in disease development. Among the chemokines upregulated highly and early upregulated during scrapie infections are ligands of CXCR3. To gain more insight into the role of CXCR3 in a prion model, CXCR3-deficient (CXCR3(-/-)) mice were infected intracerebrally with scrapie strain 139A and characterized in comparison to similarly infected wild-type controls. CXCR3(-/-) mice showed significantly prolonged survival times of up to 30 days on average. Surprisingly, however, they displayed accelerated accumulation of misfolded proteinase K-resistant prion protein PrP(Sc) and 20 times higher infectious prion titers than wild-type mice at the asymptomatic stage of the disease, indicating that these PrP isoforms may not be critical determinants of survival times. As demonstrated by immunohistochemistry, Western blotting, and gene expression analysis, CXCR3-deficient animals develop an excessive astrocytosis. However, microglia activation is reduced. Quantitative analysis of gliosis-associated gene expression alterations demonstrated reduced mRNA levels for a number of proinflammatory factors in CXCR3(-/-) compared to wild-type mice, indicating a weaker inflammatory response in the knockout mice. Taken together, this murine prion model identifies CXCR3 as disease-modifying host factor and indicates that inflammatory glial responses may act in concert with PrP(Sc) in disease development. Moreover, the results indicate that targeting CXCR3 for treatment of prion infections could prolong survival times, but the results also raise the concern that impairment of microglial migration by ablation or inhibition of CXCR3 could result in increased accumulation of misfolded PrP(Sc).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842729      PMCID: PMC2593330          DOI: 10.1128/JVI.01371-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Functional expression of CXCR3 in cultured mouse and human astrocytes and microglia.

Authors:  K Biber; I Dijkstra; C Trebst; C J A De Groot; R M Ransohoff; H W G M Boddeke
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

Review 2.  The inflammatory response in stroke.

Authors:  Qing Wang; Xian Nan Tang; Midori A Yenari
Journal:  J Neuroimmunol       Date:  2006-12-26       Impact factor: 3.478

Review 3.  Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins.

Authors:  L Meda; P Baron; G Scarlato
Journal:  Neurobiol Aging       Date:  2001 Nov-Dec       Impact factor: 4.673

4.  Secondary lymphoid tissue chemokine (CCL21) activates CXCR3 to trigger a Cl- current and chemotaxis in murine microglia.

Authors:  Angelika Rappert; Knut Biber; Christiane Nolte; Martin Lipp; Andreas Schubel; Bao Lu; Norma P Gerard; Craig Gerard; Hendrikus W G M Boddeke; Helmut Kettenmann
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

5.  Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor.

Authors:  C H Jenh; M A Cox; W Hipkin; T Lu; C Pugliese-Sivo; W Gonsiorek; C C Chou; S K Narula; P J Zavodny
Journal:  Cytokine       Date:  2001-08-07       Impact factor: 3.861

Review 6.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

Authors:  Tony Wyss-Coray
Journal:  Nat Med       Date:  2006-09       Impact factor: 53.440

Review 7.  The significance of neuroinflammation in understanding Alzheimer's disease.

Authors:  P Eikelenboom; R Veerhuis; W Scheper; A J M Rozemuller; W A van Gool; J J M Hoozemans
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

Review 8.  Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.

Authors:  Adam Szczuciński; Jacek Losy
Journal:  Acta Neurol Scand       Date:  2007-03       Impact factor: 3.209

9.  Early and rapid engraftment of bone marrow-derived microglia in scrapie.

Authors:  Josef Priller; Marco Prinz; Mathias Heikenwalder; Nicolas Zeller; Petra Schwarz; Frank L Heppner; Adriano Aguzzi
Journal:  J Neurosci       Date:  2006-11-08       Impact factor: 6.167

10.  Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Sträussler-Scheinker disease amyloid protein.

Authors:  Luana Fioriti; Nadia Angeretti; Laura Colombo; Ada De Luigi; Alessio Colombo; Claudia Manzoni; Michela Morbin; Fabrizio Tagliavini; Mario Salmona; Roberto Chiesa; Gianluigi Forloni
Journal:  J Neurosci       Date:  2007-02-14       Impact factor: 6.167

View more
  26 in total

Review 1.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  Identification of chemoattractive factors involved in the migration of bone marrow-derived mesenchymal stem cells to brain lesions caused by prions.

Authors:  Chang-Hyun Song; Osamu Honmou; Hidefumi Furuoka; Motohiro Horiuchi
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  Region-specific glial homeostatic signature in prion diseases is replaced by a uniform neuroinflammation signature, common for brain regions and prion strains with different cell tropism.

Authors:  Natallia Makarava; Jennifer Chen-Yu Chang; Kara Molesworth; Ilia V Baskakov
Journal:  Neurobiol Dis       Date:  2020-01-27       Impact factor: 5.996

4.  Early cytokine elevation, PrPres deposition, and gliosis in mouse scrapie: no effect on disease by deletion of cytokine genes IL-12p40 and IL-12p35.

Authors:  Déborah Tribouillard-Tanvier; Brent Race; James F Striebel; James A Carroll; Katie Phillips; Bruce Chesebro
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

5.  CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model.

Authors:  Marius Krauthausen; Markus P Kummer; Julian Zimmermann; Elisabet Reyes-Irisarri; Dick Terwel; Bruno Bulic; Michael T Heneka; Marcus Müller
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

6.  Striatal pathology underlies prion infection-mediated hyperactivity in mice.

Authors:  Keith M Gunapala; Daniel Chang; Cynthia T Hsu; Kebreten Manaye; Ryan M Drenan; Robert C Switzer; Andrew D Steele
Journal:  Prion       Date:  2010-10-22       Impact factor: 3.931

7.  Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levels.

Authors:  Déborah Tribouillard-Tanvier; James F Striebel; Karin E Peterson; Bruce Chesebro
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

8.  Critical Role of the CXCL10/C-X-C Chemokine Receptor 3 Axis in Promoting Leukocyte Recruitment and Neuronal Injury during Traumatic Optic Neuropathy Induced by Optic Nerve Crush.

Authors:  Yonju Ha; Hua Liu; Shuang Zhu; Panpan Yi; Wei Liu; Jared Nathanson; Rakez Kayed; Bradford Loucas; Jiaren Sun; Laura J Frishman; Massoud Motamedi; Wenbo Zhang
Journal:  Am J Pathol       Date:  2016-12-10       Impact factor: 4.307

9.  Absence of CD14 delays progression of prion diseases accompanied by increased microglial activation.

Authors:  Keiko Sakai; Rie Hasebe; Yusuke Takahashi; Chang-Hyun Song; Akio Suzuki; Takeshi Yamasaki; Motohiro Horiuchi
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

Review 10.  The immunobiology of prion diseases.

Authors:  Adriano Aguzzi; Mario Nuvolone; Caihong Zhu
Journal:  Nat Rev Immunol       Date:  2013-11-05       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.